We are live on ! Find out more
FOLD

Amicus Therapeutics

Delisted

FOLD was delisted on the 24th of April, 2026.

332 hedge funds and large institutions have $4.57B invested in Amicus Therapeutics in 2025 Q4 according to their latest regulatory filings, with 97 funds opening new positions, 112 increasing their positions, 85 reducing their positions, and 44 closing their positions.

New
Increased
Maintained
Reduced
Closed

225% more funds holding in top 10

Funds holding in top 10: 413 (+9)

120% more first-time investments, than exits

New positions opened: 97 | Existing positions closed: 44

86% more capital invested

Capital invested by funds: $2.46B → $4.57B (+$2.11B)

32% more repeat investments, than reductions

Existing positions increased: 112 | Existing positions reduced: 85

16% more funds holding

Funds holding: 287332 (+45)

2.77% more ownership

Funds ownership: 101.3%104.07% (+2.8%)

19% less call options, than puts

Call options by funds: $18.8M | Put options by funds: $23.1M

Holders
332
Holders Change
+45
Holders Change %
+15.68%
% of All Funds
4.04%
Holding in Top 10
13
Holding in Top 10 Change
+9
Holding in Top 10 Change %
+225%
% of All Funds
0.16%
New
97
Increased
112
Reduced
85
Closed
44
Calls
$18.8M
Puts
$23.1M
Net Calls
-$4.32M
Net Calls Change
-$4.52M
Name Holding Trade Value Shares
Change
Change in
Stake
BlackRock
1
BlackRock
New York
$463M +$65.6M +6,675,416 +26%
Vanguard Group
2
Vanguard Group
Pennsylvania
$423M +$1.66M +168,667 +0.6%
HI
3
HBK Investments
Texas
$217M +$150M +15,250,000 New
State Street
4
State Street
Massachusetts
$211M +$32.1M +3,270,375 +28%
PCM
5
Pentwater Capital Management
Florida
$164M +$113M +11,500,000 New
BG
6
Bellevue Group
Switzerland
$153M +$105M +10,735,195 New
William Blair Investment Management
7
William Blair Investment Management
Illinois
$151M -$50.3M -5,121,523 -33%
Geode Capital Management
8
Geode Capital Management
Massachusetts
$105M +$2.42M +246,174 +3%
PA
9
Perceptive Advisors
New York
$90.7M
Goldman Sachs
10
Goldman Sachs
New York
$87.5M +$23.2M +2,358,738 +62%
UBS Group
11
UBS Group
Switzerland
$83.9M +$40.9M +4,162,433 +240%
Morgan Stanley
12
Morgan Stanley
New York
$78M +$22.4M +2,281,019 +71%
SCM
13
Soleus Capital Management
Connecticut
$74.2M +$5.08M +517,284 +11%
PAI
14
Palo Alto Investors
California
$74.1M -$1.59M -162,031 -3%
Balyasny Asset Management
15
Balyasny Asset Management
Illinois
$73M +$36.8M +3,747,363 +272%
Citadel Advisors
16
Citadel Advisors
Florida
$72.6M -$31M -3,153,344 -38%
NAMI
17
Nomura Asset Management International
Pennsylvania
$72.2M +$49.8M +5,069,590 New
SFM
18
Soros Fund Management
New York
$71.2M +$49.1M +5,000,000 New
N
19
Nuveen
North Carolina
$65.9M +$57.3K +5,828 +0.1%
Qube Research & Technologies (QRT)
20
Qube Research & Technologies (QRT)
United Kingdom
$63.1M +$26.4M +2,685,100 +153%
MF
21
Magnetar Financial
Illinois
$56.5M +$39M +3,967,915 New
JP Morgan Chase
22
JP Morgan Chase
New York
$52.9M +$15.7M +1,601,197 +76%
RHJA
23
Rice Hall James & Associates
California
$50M +$735K +74,854 +2%
Deutsche Bank
24
Deutsche Bank
Germany
$49.2M +$9.59M +976,630 +39%
Bank of America
25
Bank of America
North Carolina
$49M -$36.1M -3,670,829 -52%

FOLD Hedge Fund Activity: Q4 2025 in Review

332 of the 8,227 institutional investors tracked by Wall St. Rank reported a position in Amicus Therapeutics (FOLD) for Q4 2025, worth a combined $4.57B — up 86% from $2.46B a quarter earlier.

Buyers outnumbered sellers: 97 funds opened new FOLD positions and 44 closed out — a net gain of 53 holders — while 112 added to existing stakes and 85 trimmed.

The largest buyer was HBK Investments, opening a new position worth an estimated $150M. The largest seller was Wellington Management Group, cutting an estimated $268M.

  • 332 institutional investors held Amicus Therapeutics (FOLD) as of Q4 2025, up from 287 in Q3 2025.
  • Funds reported $4.57B of Amicus Therapeutics stock for Q4 2025, up 86% quarter-over-quarter.
  • 97 funds opened new Amicus Therapeutics positions in Q4 2025 and 44 closed out, a net change of +53 holders.
  • The largest Amicus Therapeutics buyer in Q4 2025 was HBK Investments, an estimated $150M added.
  • The largest Amicus Therapeutics seller in Q4 2025 was Wellington Management Group, an estimated $268M sold.

Based on aggregated 13F filings for Q4 2025.